Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Modular Medical (NASDAQ: MODD) Gets FDA Clearance for Pivot Insulin Pump Software Updates

Modular Medical, Inc. (NASDAQ: MODD) secured FDA 510(k) clearance for software updates to its Pivot tubeless insulin pump, a move that enhances user-interface features and bolus delivery options.

Nitish Kishor | 04 September 2026

Penny Stock Hyperfine (NASDAQ:HYPR) Stock: Is Portable MRI Adoption Accelerating?

Penny stock Hyperfine (NASDAQ:HYPR) is a medical-technology company that has developed a portable, AI-powered magnetic-resonance-imaging system, marketed as the Swoop system, designed to provide brain imaging at the point of care. Shares closed at $0.84 at last closing, up 3.85%.

Nitish Kishor | 04 September 2026

Becton Dickinson (NYSE:BDX) Stock: Does the Planned Separation Change the Story?

Becton Dickinson (NYSE:BDX), known as BD, is a leading global medical-technology company that makes and sells medical devices, instrument systems, and reagents, spanning medication delivery and management, diagnostics, and biosciences. Shares closed at $187.62 at last closing, up 0.05%.

Nitish Kishor | 04 September 2026

Oculis Holding (NASDAQ:OCS): Neuro-Ophthalmology Pipeline Still the Catalyst to Watch

Oculis Holding (NASDAQ:OCS) is a clinical-stage biopharmaceutical company focused on developing treatments for ophthalmic and related diseases, with a pipeline that includes candidates for conditions such as diabetic macular edema, dry-eye disease, and, notably, acute optic neuritis, a neuro-ophthalmic condition. Shares closed at $12.17 …

Nitish Kishor | 04 September 2026

Penny Stock OKYO Pharma (NASDAQ:OKYO) Falls to $1.55: What Would It Take to Revive the Stock?

Penny stock OKYO Pharma (NASDAQ:OKYO) is a clinical-stage biopharmaceutical company developing therapies for ophthalmic and inflammatory diseases, with its lead candidate, urcosimod, being studied for neuropathic corneal pain, a serious and underserved eye condition, and for dry-eye disease. Shares closed at $1.55 at last …

Nitish Kishor | 04 September 2026

This Clinical-Stage Oncology Stock Has Gone Quiet: Is a Surprise Move Coming?

This clinical-stage oncology penny stock, PMV Pharmaceuticals (NASDAQ:PMVP), is developing cancer therapies that target the p53 tumor-suppressor pathway, one of the most commonly mutated pathways in cancer. Shares closed at $1.24 at last closing, down 1.59%.

Nitish Kishor | 04 September 2026

Ultragenyx Pharmaceutical (NASDAQ:RARE) Plunges 44% as Phase 3 Angelman Syndrome Trial Fails to Meet Endpoints

Ultragenyx Pharmaceutical (NASDAQ:RARE) shares closed at $14.85 at last closing, down 44.03%, after the company announced that its Phase 3 Aspire study of apazunersen (GTX-102) in Angelman syndrome did not achieve its primary endpoint of change from baseline in Bayley-4 cognitive raw score, nor …

Nitish Kishor | 04 September 2026

MediWound (NASDAQ:MDWD): Wound-Care Pipeline Progress Still in Focus

MediWound (NASDAQ:MDWD) is a biopharmaceutical company focused on wound care and tissue repair, with products and candidates that use enzymatic technologies to remove dead or damaged tissue. Shares closed at $13.21 at last closing, up 1.15%.

Nitish Kishor | 04 September 2026

The Cigna Group (NYSE:CI): Health-Services Diversification Remains the Story

The Cigna Group (NYSE:CI) is a large health-services company operating two main businesses: Cigna Healthcare, which provides health-insurance and benefits plans, and Evernorth Health Services, which includes its pharmacy-benefit-management operations through Express Scripts, specialty pharmacy, and other health services. Shares closed at $286.26 at …

Nitish Kishor | 04 September 2026

Arcturus Therapeutics (NASDAQ:ARCT): Is the mRNA Pipeline the Next Catalyst to Watch?

Arcturus Therapeutics (NASDAQ:ARCT) is a biopharmaceutical company developing messenger-RNA and self-amplifying-RNA medicines and vaccines, using its proprietary RNA and lipid-nanoparticle-delivery technologies. No last-closing price move has been supplied for this ticker, so no directional stock-price claim is made here.

Nitish Kishor | 04 September 2026
Support

Hi! How can we help you today?

Loading…